MCID: PPL007
MIFTS: 42

Papillary Serous Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Papillary Serous Adenocarcinoma

MalaCards integrated aliases for Papillary Serous Adenocarcinoma:

Name: Papillary Serous Adenocarcinoma 12 15
Serous Surface Papillary Carcinoma 12 70
Micropapillary Serous Carcinoma 12 17
Papillary Serous Cystadenocarcinoma 70
Papillary Serous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2632
NCIt 50 C4182
SNOMED-CT 67 716649003
UMLS 70 C0334359 C0334361

Summaries for Papillary Serous Adenocarcinoma

Disease Ontology : 12 A papillary adenocarcinoma that derives from epithelial cells originating in glandular tissue, which form complex papillary structures with psammoma bodies.

MalaCards based summary : Papillary Serous Adenocarcinoma, also known as serous surface papillary carcinoma, is related to endometrial serous adenocarcinoma and papillary carcinoma. An important gene associated with Papillary Serous Adenocarcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are Pathways in cancer and Endometrial cancer. The drugs Everolimus and Letrozole have been mentioned in the context of this disorder. Affiliated tissues include breast, ovary and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Papillary serous cystadenocarcinomas are the most common form of malignant ovarian cancer making up 26... more...

Related Diseases for Papillary Serous Adenocarcinoma

Diseases related to Papillary Serous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 508)
# Related Disease Score Top Affiliating Genes
1 endometrial serous adenocarcinoma 31.3 WT1 TP53 PGR KRAS BRCA1
2 papillary carcinoma 30.5 PGR PAX8 NKX2-1 KRT7 KRT20 CALB2
3 fallopian tube adenocarcinoma 30.4 CALB2 BRCA1
4 large cell neuroendocrine carcinoma 30.4 NKX2-1 KRT7 KRT20
5 ovarian brenner tumor 30.3 WT1 KRT7 KRT20
6 angiomyolipoma 30.2 PGR PAX8 KRT7
7 endometrial adenocarcinoma 30.1 TP53 PGR KRT7 KRAS
8 endometrial hyperplasia 30.1 TP53 PGR KRAS
9 malignant epithelial mesothelioma 30.1 CEACAM5 CALB2
10 clear cell adenocarcinoma 30.0 TP53 PAX8 KRT7 KRT20
11 primary peritoneal carcinoma 30.0 TP53 PGR BRCA2 BRCA1
12 bilateral breast cancer 30.0 TP53 PGR BRCA2 BRCA1
13 transitional cell carcinoma 29.9 TP53 KRT7 KRT20 HRAS
14 intestinal obstruction 29.9 KRT7 KRT20 CEACAM5
15 adenofibroma 29.9 TP53 PAX8 KRT7 CALB2
16 uterine carcinosarcoma 29.8 TP53 PGR HRAS BRCA1
17 neuroendocrine carcinoma 29.8 NKX2-1 KRT7 KRT20 CEACAM5
18 in situ carcinoma 29.8 TP53 PGR HRAS BRCA2 BRCA1
19 ovarian disease 29.7 TP53 PGR MIR30A BRCA2 BRCA1
20 fallopian tube carcinoma 29.6 TP53 PGR PAX8 BRCA2 BRCA1
21 polycystic liver disease 1 with or without kidney cysts 29.6 KRT7 KRT20 CEACAM5 CALB2
22 small cell carcinoma 29.6 TP53 NKX2-1 KRT7 KRT20 KRAS BRCA2
23 adenosquamous carcinoma 29.4 TP53 NKX2-1 KRT7 KRAS CEACAM5
24 mesothelioma, malignant 29.4 WT1 NKX2-1 KRT7 KRT20 CEACAM5 CALB2
25 cervical adenocarcinoma 29.4 TP53 KRT7 KRT20 KRAS CEACAM5 CALB2
26 endocervical carcinoma 29.4 TP53 PGR PAX8 KRT7 CEACAM5
27 myoma 29.3 TP53 PGR KRAS CEACAM5
28 cervix carcinoma 29.3 TP53 PGR PAX8 KRT7 CEACAM5
29 serous cystadenocarcinoma 29.2 WT1 TP53 PGR PAX8 MIR30A KRAS
30 endocervical adenocarcinoma 29.2 TP53 PGR PAX8 KRT7 KRT20 CEACAM5
31 hereditary breast ovarian cancer syndrome 29.2 TP53 KRAS HRAS BRCA2 BRCA1
32 carcinosarcoma 29.1 TP53 PGR PAX8 KRT7 KRAS HRAS
33 ovarian serous carcinoma 29.1 WT1 TP53 PAX8 KRAS CALB2 BRCA1
34 benign mesothelioma 29.1 WT1 NKX2-1 KRT7 KRT20 CEACAM5 CALB2
35 adenocarcinoma 29.0 TP53 NKX2-1 KRT7 KRT20 KRAS HRAS
36 cystadenocarcinoma 29.0 TP53 PGR MIR30A KRT7 HRAS CEACAM5
37 wilms tumor 1 28.3 WT1 TP53 PGR PAX8 NKX2-1 KRT7
38 peritoneum cancer 28.2 WT1 TP53 PAX8 KRT7 CEACAM5 CALB2
39 pancreatic cancer 28.1 TP53 MIR30A KRT7 KRT20 KRAS HRAS
40 papillary adenocarcinoma 28.1 TP53 PGR NKX2-1 MIR509-1 MIR30E MIR30A
41 ovarian cystadenocarcinoma 27.8 TP53 PAX8 MIR30A KRAS HRAS CEACAM5
42 endometrial cancer 27.4 WT1 TP53 PGR PAX8 NKX2-1 KRT7
43 ovary adenocarcinoma 27.2 WT1 TP53 PGR PAX8 MIR30A KRT7
44 ovarian cancer 27.2 WT1 TP53 PGR PAX8 MIR30E MIR30A
45 ovary papillary carcinoma 11.4
46 bartholin's gland adenoid cystic carcinoma 10.4 PGR KRT7
47 lung meningioma 10.4 PGR NKX2-1
48 nonmucinous bronchioloalveolar adenocarcinoma 10.4 NKX2-1 KRT20
49 oncocytic breast carcinoma 10.4 PGR KRT7
50 atrophic vulva 10.4 KRT7 KRT20

Graphical network of the top 20 diseases related to Papillary Serous Adenocarcinoma:



Diseases related to Papillary Serous Adenocarcinoma

Symptoms & Phenotypes for Papillary Serous Adenocarcinoma

GenomeRNAi Phenotypes related to Papillary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 35)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.09 CDKL2 HRAS KRAS
2 Decreased viability GR00055-A-2 10.09 CDKL2 HRAS KRAS
3 Decreased viability GR00055-A-3 10.09 KRAS
4 Decreased viability GR00106-A-0 10.09 KRAS
5 Decreased viability GR00221-A-1 10.09 CDKL2 HRAS KRAS STK36
6 Decreased viability GR00221-A-2 10.09 BRCA1 CDKL2 HRAS KRAS STK36
7 Decreased viability GR00221-A-3 10.09 BRCA1 HRAS
8 Decreased viability GR00221-A-4 10.09 CDKL2 STK36
9 Decreased viability GR00301-A 10.09 BRCA1 KRAS
10 Decreased viability GR00342-S-1 10.09 CDKL2
11 Decreased viability GR00381-A-1 10.09 CDKL2 KRAS
12 Decreased viability GR00386-A-1 10.09 CDKL2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.7 WT1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.7 ANXA4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.7 WT1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.7 BRCA1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.7 BRCA1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-145 9.7 WT1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.7 WT1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.7 PAX8
21 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.7 BRCA1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.7 HRAS
23 Increased shRNA abundance (Z-score > 2) GR00366-A-200 9.7 ANXA4
24 Increased shRNA abundance (Z-score > 2) GR00366-A-204 9.7 BRCA1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.7 BRCA1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.7 WT1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-28 9.7 HRAS
28 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.7 WT1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.7 ANXA4 WT1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.7 WT1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.7 ANXA4
32 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.7 ANXA4
33 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.7 HRAS
34 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.7 WT1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.7 HRAS

MGI Mouse Phenotypes related to Papillary Serous Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.02 BRCA1 BRCA2 HRAS KRAS NKX2-1 PAX8
2 neoplasm MP:0002006 9.86 BRCA1 BRCA2 HRAS KRAS NKX2-1 PGR
3 no phenotypic analysis MP:0003012 9.81 CDKL2 HRAS KRAS NKX2-1 PAX8 PGR
4 normal MP:0002873 9.65 BRCA1 BRCA2 CALB2 HRAS KRAS NKX2-1
5 renal/urinary system MP:0005367 9.28 ANXA4 BRCA1 HRAS KRAS KRT7 PAX8

Drugs & Therapeutics for Papillary Serous Adenocarcinoma

Drugs for Papillary Serous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177 70789204
2
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
3 Immunosuppressive Agents Phase 2, Phase 3
4 Immunologic Factors Phase 2, Phase 3
5 Hormones Phase 2, Phase 3
6 Hormone Antagonists Phase 2, Phase 3
7 Estrogens Phase 2, Phase 3
8 Estrogen Antagonists Phase 2, Phase 3
9 Estrogen Receptor Antagonists Phase 2, Phase 3
10 Aromatase Inhibitors Phase 2, Phase 3
11
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
12
Cimetidine Approved, Investigational Phase 2 51481-61-9 2756
13
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
14
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
15
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
16
Promethazine Approved, Investigational Phase 2 60-87-7 4927
17
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
18
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
19 Hypnotics and Sedatives Phase 2
20 Anesthetics Phase 2
21 Gastrointestinal Agents Phase 2
22 Neurotransmitter Agents Phase 2
23 Antacids Phase 2
24 Anesthetics, Local Phase 2
25 Anti-Ulcer Agents Phase 2
26 Histamine H2 Antagonists Phase 2
27 glucocorticoids Phase 2
28 Antineoplastic Agents, Hormonal Phase 2
29 Anti-Inflammatory Agents Phase 2
30 Dermatologic Agents Phase 2
31 Histamine Antagonists Phase 2
32
Histamine Phosphate Phase 2 51-74-1 65513
33 Anti-Allergic Agents Phase 2
34 Histamine H1 Antagonists Phase 2
35 Antiemetics Phase 2
36 Cytochrome P-450 Enzyme Inhibitors Phase 2
37 Antimitotic Agents Phase 1, Phase 2
38 Albumin-Bound Paclitaxel Phase 1, Phase 2
39 Tubulin Modulators Phase 1, Phase 2
40 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596
41 Protein Kinase Inhibitors Phase 1, Phase 2
42
Clotrimazole Approved, Vet_approved Phase 1 23593-75-1 2812
43
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
44
Sirolimus Approved, Investigational Phase 1 53123-88-9 5284616 6436030
45 Anti-Bacterial Agents Phase 1
46 Antibiotics, Antitubercular Phase 1
47 Antifungal Agents Phase 1
48 Anti-Infective Agents Phase 1
49
Levoleucovorin Approved, Investigational 68538-85-2 149436
50
Progesterone Approved, Vet_approved 57-83-0 5994

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 CRAD001X2401: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Completed NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
2 A Phase II Study: Paclitaxel and Pelvic Radiation for Stage I-IIIA Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
3 A Pilot Phase II Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
4 Phase II Study On Paclitaxel In Recurrent Uterine Papillary Serous Carcinoma (UPSC) Completed NCT00022620 Phase 2 paclitaxel
5 A Phase I/II Study of Gleevec/Taxol in Patients With Newly Diagnosed Stage IIIC or IV or Recurrent (Any Stage) Uterine Papillary Serous Carcinoma (UPSC) Terminated NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
6 Safety and Efficacy of RO4929097 in Combination With Temsirolimus: A Pharmacokinetic and Pharmacodynamic Phase I Study in Patients With Advanced Solid Tumours With an Expansion of Cohort With Patients With Recurrent/Metastatic Endometrial and Renal Cell Cancers Completed NCT01198184 Phase 1 temsirolimus;gamma-secretase/Notch signalling pathway inhibitor RO4929097
7 The Use and Safety of Metformin, Carboplatin and Paclitaxel in Non-Diabetic Patients With Recurrent, Platinum Sensitive Ovarian Cancer and the Feasibility of Using a Core Biopsy for RNA-Seq Withdrawn NCT02050009 Phase 1 metformin hydrochloride;carboplatin;paclitaxel
8 The Role of Synuclein-gamma (SNCG) in the Carcinogenesis of Uterine Papillary Serous Carcinoma Not yet recruiting NCT01344837

Search NIH Clinical Center for Papillary Serous Adenocarcinoma

Genetic Tests for Papillary Serous Adenocarcinoma

Anatomical Context for Papillary Serous Adenocarcinoma

MalaCards organs/tissues related to Papillary Serous Adenocarcinoma:

40
Breast, Ovary, Lung, Thyroid, Colon, Liver, Cervix

Publications for Papillary Serous Adenocarcinoma

Articles related to Papillary Serous Adenocarcinoma:

(show top 50) (show all 138)
# Title Authors PMID Year
1
Primary retroperitoneal serous adenocarcinoma: A case report of rare malignancy with literature review. 61
33402586 2020
2
Suppression of autophagy enhances preferential toxicity of epothilone A and epothilone B in ovarian cancer cells. 61
31029905 2019
3
Brain Metastasis in Papillary Serous Adenocarcinoma of the Endometrium. 61
30991420 2019
4
Clinical and EEG Characteristics of Ifosfamide-Related Encephalopathy. 61
30694943 2019
5
Ovarian cancer unmasked by technetium-99m bone scintigraphy and single-photon emission computed tomography-computed tomography. 61
30774548 2019
6
[A Case of Splenic Metastasis from Serous Surface Papillary Carcinoma of the Peritoneum Treated by Laparoscopic Splenectomy]. 61
29650839 2018
7
Primary Adenocarcinoma of the Fallopian Tube: A Rare Entity. 61
29207787 2017
8
Primary Peritoneal Serous Carcinoma in Men: A Rare and Non-BRCA-associated Entity. 61
28551646 2017
9
Long-term survival of high-grade primary peritoneal papillary serous adenocarcinoma: a case report and literature review. 61
28399919 2017
10
[Clinical-based study of ovarian cancer patients with and without BRCA1/2 genes mutation: clinical features and pedigree analysis]. 61
28190311 2017
11
Filarial worm residing in ovarian papillary serous adenocarcinoma-A rare case report. 61
27444355 2016
12
FDG PET/CT Imaging of Calcified Sister Mary Joseph Nodule. 61
27405031 2016
13
Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation. 61
27426853 2016
14
Hydrosalpinx as a Rare Presentation of Synchronous Ovarian and Endometrial Carcinoma - A Case Report. 61
27630913 2016
15
In vitro effect of IL-17D on human ovarian carcinoma cells and inherent immunity. 61
27655504 2016
16
Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy. 61
26825824 2016
17
Bilateral primary fallopian tube papillary serous carcinoma in postmenopausal woman: Report of two cases. 61
27134480 2016
18
Colonic Metastasis Presenting as an Intraluminal Fungating Mass 8 Years After Surgery for Ovarian Cancer. 61
26576399 2015
19
Reduced expression and growth inhibitory activity of the aging suppressor klotho in epithelial ovarian cancer. 61
25827069 2015
20
Epothilone B induces human ovarian cancer OV-90 cell apoptosis via external pathway. 61
25721485 2015
21
Abdominal aortic resection and Y-graft placement to achieve complete cytoreduction in stage IIIc ovarian carcinoma. 61
24413236 2014
22
[Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases]. 61
24273914 2013
23
Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary. 61
23290009 2013
24
Multiple brain metastases in a patient with uterine papillary serous adenocarcinoma: Treatment options for this rarely seen metastatic brain tumor. 61
24032086 2013
25
Papillary serous carcinoma of the cervix mixed with squamous cells: A report of the first case. 61
24371711 2013
26
Malignant mixed mullerian tumor of endometrium coexisting with bilateral papillary serous adenocarcinoma of fallopian tube: a rare case report. 61
24293882 2012
27
High-grade primary peritoneal serous papillary carcinoma with a wide differential diagnosis: a diagnostic challenge. 61
23547430 2012
28
Tumorigenic potential of pituitary tumor transforming gene (PTTG) in vivo investigated using a transgenic mouse model, and effects of cross breeding with p53 (+/-) transgenic mice. 61
23164239 2012
29
Papillary-serous adenocarcinoma of the uterine cervix during tamoxifen therapy after bilateral breast cancer. 61
23155282 2012
30
[Papillary serous adenocarcinoma of the endometrium and ovary]. 61
22987388 2012
31
Endometrioid adenocarcinoma with high-grade transformation with serous and choriocarcinomatous differentiation - a case report. 61
22211141 2012
32
F-18 fluoride uptake in calcified extraosseous metastases from ovarian papillary serous adenocarcinoma. 61
22157054 2012
33
Multiple gastric metastases from ovarian carcinoma diagnosed by endoscopic ultrasound with fine needle aspiration. 61
22811942 2012
34
Pancreatic metastasis of high-grade papillary serous ovarian carcinoma mimicking primary pancreas cancer: a case report. 61
22829843 2012
35
Gastrointestinal stromal tumor with synchronous isolated parenchymal splenic metastasis of ovarian cancer. 61
22340419 2011
36
Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression. 61
22017790 2011
37
A single-institution evaluation of factors important in fallopian tube carcinoma recurrence and survival. 61
21720254 2011
38
[Epidemiological profile of ovarian cancer]. 61
21966857 2011
39
Endometrial cancer, types, prognosis, female hormones and antihormones. 61
21426234 2011
40
[A case of serous surface papillary carcinoma of the peritoneum metastatic to the brain]. 61
21628741 2011
41
Papillary serous adenocarcinoma of the uterine cervix: a case report. 61
21614930 2011
42
Conservative surgery in cervical cancer: report of two radical abdominal trachelectomies and literature review. 61
22335046 2011
43
Consequences of abdominal adenocarcinoma in post-menopausal woman in relation to surgical and non-surgical management. 61
21863621 2011
44
Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. 61
21041624 2010
45
Validation of serum biomarkers for detection of early- and late-stage endometrial cancer. 61
19766980 2010
46
Acute gastric outlet obstruction secondary to papillary serous adenocarcinoma of the endometrium with peritoneal psammomatous implants: a case report. 61
19132421 2010
47
Cisplatinum and docetaxel for ovarian cancer in pregnancy. 61
19242705 2009
48
F-18 FDG PET-CT findings in a case of normal-sized ovarian cancer syndrome. 61
19893409 2009
49
99mTc-MDP and 18F-FDG uptake in calcified metastatic lesions from ovarian papillary serous adenocarcinoma. 61
19936349 2009
50
Successful Treatment of Primary Vaginal Papillary Serous Adenocarcinoma Using Chemoradiation Followed by Brachytherapy. 61
20740170 2009

Variations for Papillary Serous Adenocarcinoma

Expression for Papillary Serous Adenocarcinoma

Search GEO for disease gene expression data for Papillary Serous Adenocarcinoma.

Pathways for Papillary Serous Adenocarcinoma

Pathways related to Papillary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1 12.65 TP53 PAX8 KRAS HRAS BRCA2
2
Show member pathways
12.58 TP53 PAX8 KRAS HRAS BRCA2
3
Show member pathways
12.36 TP53 KRAS HRAS BRCA2 BRCA1
4
Show member pathways
12.32 TP53 KRAS HRAS BRCA2 BRCA1
5
Show member pathways
12.1 TP53 PGR KRAS HRAS BRCA2 BRCA1
6 11.75 TP53 KRAS BRCA2 BRCA1
7
Show member pathways
11.61 TP53 BRCA2 BRCA1
8 11.6 PGR KRT20 KRAS HRAS
9 11.59 TP53 MIR30E MIR30A KRAS HRAS BRCA1
10 11.52 TP53 KRAS HRAS
11 11.48 TP53 KRAS HRAS
12 11.44 TP53 KRAS HRAS
13 11.4 TP53 HRAS BRCA1

GO Terms for Papillary Serous Adenocarcinoma

Biological processes related to Papillary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.98 WT1 TP53 PGR PAX8 NKX2-1 HRAS
2 positive regulation of transcription, DNA-templated GO:0045893 9.88 WT1 TP53 PAX8 NKX2-1 BRCA2 BRCA1
3 Ras protein signal transduction GO:0007265 9.69 TP53 KRAS HRAS
4 double-strand break repair GO:0006302 9.63 TP53 BRCA2 BRCA1
5 cellular response to gonadotropin stimulus GO:0071371 9.49 WT1 PAX8
6 response to isolation stress GO:0035900 9.48 KRAS HRAS
7 metanephric S-shaped body morphogenesis GO:0072284 9.37 WT1 PAX8
8 cell aging GO:0007569 9.33 TP53 HRAS BRCA2
9 metanephric epithelium development GO:0072207 9.32 WT1 PAX8
10 chordate embryonic development GO:0043009 9.26 BRCA2 BRCA1
11 positive regulation of gene expression GO:0010628 9.17 WT1 TP53 NKX2-1 MIR509-1 KRAS HRAS
12 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.13 TP53 BRCA2 BRCA1

Molecular functions related to Papillary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region sequence-specific DNA binding GO:0000976 9.02 WT1 TP53 PAX8 NKX2-1 BRCA1

Sources for Papillary Serous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....